Drug Profile
Glimepiride extended release/metformin extended release - GSK
Alternative Names: Metformin extended release/glimepiride extended release - GSKLatest Information Update: 10 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antihyperglycaemics; Biguanides; Small molecules; Sulfones; Sulfonylureas
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Insulinotropin agonists; Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 30 Aug 2013 GlaxoSmithKline terminates phase I trial in Type 2 diabetes mellitus (in volunteers) in Australia (NCT01725672)
- 01 Sep 2012 Phase-I clinical trials in Type-2 diabetes mellitus (in volunteers) in Australia (PO)